risedronic acid has been researched along with Bright Disease in 1 studies
Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.
Bright Disease: A historical classification which is no longer used. It described acute glomerulonephritis, acute nephritic syndrome, or acute nephritis. Named for Richard Bright.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kikuchi, Y | 1 |
| Imakiire, T | 1 |
| Yamada, M | 1 |
| Saigusa, T | 1 |
| Hyodo, T | 1 |
| Kushiyama, T | 1 |
| Higashi, K | 1 |
| Hyodo, N | 1 |
| Yamamoto, K | 1 |
| Suzuki, S | 1 |
| Miura, S | 1 |
1 trial available for risedronic acid and Bright Disease
| Article | Year |
|---|---|
Effect of risedronate on high-dose corticosteroid-induced bone loss in patients with glomerular disease.
Topics: Adolescent; Adult; Aged; Bone Density Conservation Agents; Bone Diseases, Metabolic; Dose-Response R | 2007 |